Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001737287-25-000003
Filing Date
2025-01-23
Accepted
2025-01-23 16:30:31
Documents
3
Period of Report
2025-01-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1737667821.html 4  
1 FORM 4 wk-form4_1737667821.xml 4 4083
2 EX-24 zroberts-allogenexsectio.htm EX-24 3903
3 zroberts-allogenexsectio001.jpg GRAPHIC 220223
  Complete submission text file 0001737287-25-000003.txt   312810
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O INSTIL BIO, INC. 3963 MAPLE AVENUE, SUITE 350 DALLAS TX 75219
Business Address
Roberts Zachary (Reporting) CIK: 0001851044 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 25550548